WP
VIR icon

Woodline Partners’s Vir Biotechnology VIR Stock Holding History

Woodline Partners’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-466,737
Closed -$3.02M – 1052
2025
Q1 		$3.02M Buy
466,737
+331,701
+246% +$2.95M 0.02% 606
2024
Q4 		$991K Buy
+135,036
New +$1.07M 0.01% 762
2023
Q3 		– Sell
-81,386
Closed -$2M – 749
2023
Q2 		$2M Buy
+81,386
New +$2.04M 0.02% 433

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Woodline Partners's VIR Position: Q2 2025 in Review

Woodline Partners sold out of Vir Biotechnology (VIR) in Q2 2025, closing a stake of 466,737 shares — an estimated $3.02M sold.

Woodline Partners first reported a position in VIR in Q2 2023 and held it in 3 quarters. The position peaked at $3.02M in Q1 2025. 213 funds tracked by Wall St. Rank hold VIR as of Q2 2025.

  • Woodline Partners reported no remaining Vir Biotechnology position as of Q2 2025 after selling out during the quarter.
  • Woodline Partners sold 466,737 Vir Biotechnology shares in Q2 2025, an estimated $3.02M.
  • Woodline Partners first reported a position in Vir Biotechnology in Q2 2023 and held it in 3 quarters.
  • Woodline Partners's Vir Biotechnology position peaked at $3.02M in Q1 2025.
  • 213 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2025.

Based on Woodline Partners's 13F filing for Q2 2025, filed 14 Aug 2025.